GGrantIndex
← Leaderboards

Pamela Ouyang

Johns Hopkins University

$2,963,906
Attributed
$2,963,906
Total exposure
21
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $391.3K · FY200510
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10

Funding mix

By agency

NIH$2,963,906 · 21

By mechanism

R01$1,000,315 · 1
U01$732,028 · 1
R21$502,740 · 1
M01$365,926 · 17
N01$362,897 · 1

Top collaborators

No co-investigators on record.

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman SubjectAtherosclerosisHormone TherapyHuman Therapy EvaluationFemaleClinical TrialsAngiographyCoronary BypassPostmenopauseLongitudinal Human StudyPlacebosPathologic ProcessCoronary DisorderWomen'S HealthPostoperative StateCardiovascular Disorder PreventionAntioxidantsVasomotionPlatelet ActivationMedroxyprogesteroneHypertensionMyocardial InfarctionCardiovascular Disorder Risk

Grant awards (39)

Dose Ranging study of the Effects of Alpha Acid on Oxidative Stress$124,740
R21 · FY2010 · AT · contact PI
Dose Ranging study of the Effects of Alpha Acid on Oxidative Stress$189,000
R21 · FY2009 · AT · contact PI
Dose Ranging study of the Effects of Alpha Acid on Oxidative Stress$189,000
R21 · FY2008 · AT · contact PI
TRIAL TO ASSESS CHELATION THERAPY (TACT)$16,730
M01 · FY2007 · RR · contact PI
THE CLEVER STUDY$1,439
M01 · FY2007 · RR · contact PI
THE EFFECT OF STATIN USE ON VASCULAR FUNCTION IN HYPERTENSIVE SUBJECTS$511
M01 · FY2007 · RR · contact PI
PREDICTOR OF ADVANCED SUB-CLINICAL ATHEROSCLEROSIS$206
M01 · FY2007 · RR · contact PI
Serum Sex Hormonoe Levels & Subclinical Atherosclerosis$168,315
R01 · FY2006 · HL · contact PI
TRIAL TO ASSESS CHELATION THERAPY (TACT)$52,172
M01 · FY2006 · RR · contact PI
THE EFFECT OF STATIN USE ON VASCULAR FUNCTION IN HYPERTENSIVE SUBJECTS$12,310
M01 · FY2006 · RR · contact PI
Serum Sex Hormonoe Levels &Subclinical Atherosclerosis$275,500
R01 · FY2005 · HL
TRIAL TO ASSESS CHELATION THERAPY (TACT)$77,447
M01 · FY2005 · RR
THE EFFECT OF STATIN USE ON VASCULAR FUNCTION IN HYPERTENSIVE SUBJECTS$28,744
M01 · FY2005 · RR
DETERMINATION OF THE EFFECT OF HIGH-FAT FOOD ON CORONARY FLOW VELOCITY$8,784
M01 · FY2005 · RR
PREVENTION OF EVENTS WITH ACE INHIBITOR THERAPY (PEACE)$798
M01 · FY2005 · RR
Serum Sex Hormonoe Levels &Subclinical Atherosclerosis$275,250
R01 · FY2004 · HL
Prevention of Events with ACE Inhibitor Therapy (PEACE)$133,921
M01 · FY2004 · RR
Measurement of Coronary Flow Using Transthoracic Echocardiography$27,934
M01 · FY2004 · RR
Determination of the Effect of High-Fat Food on Coronary Flow Velocity$4,930
M01 · FY2004 · RR
Serum Sex Hormone Levels &Subclinical Atherosclerosis$281,250
R01 · FY2003 · HL
WOMEN'S ANGIOGRAPHIC VITAMINS AND ESTROOGENS TRIAL$0
M01 · FY2002 · RR
POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY AFTER CABG$0
M01 · FY2002 · RR
HRt &ATHEROSCLEROSIS AFTER CORONARY BYPASS &MENOPAUSE$0
M01 · FY2002 · RR
HORMONE REPLACEMENT THERAPY EFFECTS ON PROGRESSION OF ARTHEROSCLEROSIS$0
M01 · FY2002 · RR
POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY AFTER CABG$370,606
U01 · FY2001 · HL
HRt &ATHEROSCLEROSIS AFTER CORONARY BYPASS &MENOPAUSE$0
M01 · FY2001 · RR
CLINICAL UNIT FOR THE ANGIOGRAPHIC TRIAL IN WOMEN$0
N01 · FY2001 · HV
WOMEN'S ANGIOGRAPHIC VITAMINS AND ESTROOGENS TRIAL$0
M01 · FY2001 · RR
POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY AFTER CABG$0
M01 · FY2001 · RR
HORMONE REPLACEMENT THERAPY EFFECTS ON PROGRESSION OF ARTHEROSCLEROSIS$0
M01 · FY2001 · RR
CLINICAL UNIT FOR THE ANGIOGRAPHIC TRIAL IN WOMEN$362,897
N01 · FY2000 · HV
POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY AFTER CABG$361,422
U01 · FY2000 · HL
HORMONE REPLACEMENT THERAPY EFFECTS ON PROGRESSION OF ARTHEROSCLEROSIS$0
M01 · FY2000 · RR
PREVENTION OF CARDIAC EVENTS WITH ACE INHIBITORS$0
M01 · FY2000 · RR
PREVENTION OF CARDIAC EVENTS WITH ACE INHIBITORS$0
M01 · FY2000 · RR
PREVENTION OF CARDIAC EVENTS WITH ACE INHIBITORS$0
M01 · FY2000 · RR
WOMEN'S ANGIOGRAPHIC VITAMINS AND ESTROOGENS TRIAL$0
M01 · FY2000 · RR
POSTMENOPAUSAL HRT ON ATHEROSCLEROSIS AFTER CABG$0
M01 · FY2000 · RR
HRt &ATHEROSCLEROSIS AFTER CORONARY BYPASS &MENOPAUSE$0
M01 · FY2000 · RR